Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022004622 - ANTIBODY AGAINST SARS-COV-2, METHOD FOR DETECTING SARS-COV-2 USING ANTIBODY AND KIT CONTAINING ANTIBODY

Publication Number WO/2022/004622
Publication Date 06.01.2022
International Application No. PCT/JP2021/024267
International Filing Date 28.06.2021
IPC
C07K 16/10 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
C12N 15/13 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
13Immunoglobulins
C12N 15/50 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
G01N 33/53 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
G01N 33/543 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
543with an insoluble carrier for immobilising immunochemicals
Applicants
  • 公立大学法人横浜市立大学 PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY [JP]/[JP]
  • 関東化学株式会社 KANTO KAGAKU KABUSHIKI KAISHA [JP]/[JP]
Inventors
  • 梁 明秀 RYO, Akihide
  • 山岡 悠太郎 YAMAOKA, Yutaro
  • 菊池 沙也香 KIKUCHI, Sayaka
Agents
  • 葛和 清司 KUZUWA, Kiyoshi
Priority Data
2020-11198429.06.2020JP
Publication Language Japanese (ja)
Filing Language Japanese (JA)
Designated States
Title
(EN) ANTIBODY AGAINST SARS-COV-2, METHOD FOR DETECTING SARS-COV-2 USING ANTIBODY AND KIT CONTAINING ANTIBODY
(FR) ANTICORPS CONTRE LE SARS-COV-2, PROCÉDÉ DE DÉTECTION DU SARS-COV-2 À L'AIDE D'UN ANTICORPS ET KIT CONTENANT UN ANTICORPS
(JA) SARS-CoV-2に対する抗体、該抗体を用いてSARS-CoV-2を検出する方法および該抗体を含むキット
Abstract
(EN) The present invention addresses the problem of providing a means for detecting a constituting protein of nucleocapsid derived from SARS-CoV-2. This problem has been solved by providing an antibody binding to a constituting protein of nucleocapsid derived from SARS-CoV-2 or a fragment of the antibody, a method for detecting a constituting protein of the SARS-CoV-2-derived nucleocapsid with the use of the antibody or a fragment thereof, a kit for detecting a constituting protein of the SARS-CoV-2-derived nucleocapsid, said kit containing the antibody or a fragment thereof, etc.
(FR) La présente invention aborde le problème de la fourniture d'un moyen de détection d'une protéine constitutive d'une nucléocapside dérivée du SARS-CoV-2. Ce problème a été résolu par la fourniture d'un anticorps se liant à une protéine constitutive d'une nucléocapside dérivée du SARS-CoV-2 ou d'un fragment de l'anticorps. L'invention concerne également un procédé de détection d'une protéine constitutive de la nucléocapside dérivée du SARS-CoV 2 à l'aide de l'anticorps ou d'un fragment de celui-ci, ainsi qu'un kit de détection d'une protéine constitutive de la nucléocapside dérivée du SARS-CoV-2, ledit kit contenant l'anticorps ou un fragment de celui-ci, etc.
(JA) 本発明は、SARS-CoV-2由来ヌクレオカプシドを構成するタンパク質を検出するための手段を提供することを課題とする。SARS-CoV-2由来ヌクレオカプシドを構成するタンパク質に結合する抗体またはその断片、該抗体またはその断片を用いてSARS-CoV-2由来ヌクレオカプシドを構成するタンパク質を検出する方法、および該抗体またはその断片を含むSARS-CoV-2由来ヌクレオカプシドを構成するタンパク質を検出するためのキット等を提供することにより、上記課題が達成された。
Latest bibliographic data on file with the International Bureau